US FDA Rejects to Give Approval to Anemia Drug Developed by FibroGen
On Wednesday, 11th August 2021, the company ‘FibroGen Inc.’, said the United States Food and Drug Administration has rejected the approval for the drug of the company for the treatment of the anemia of chronic kidney disease, that has been citing the need for an additional study. In July 2021, a panel of the experts […]
Continue Reading